Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $1,753,274
Globe Newswire•13/10/2026•08:00 ET
0
Key Highlights
- ➤272,671 NTRBW warrants exercised at $6.43, generating $1,753,274.53
- ➤Proceeds will fund AVERSA Fentanyl clinical development and FDA NDA submission
- ➤Nutriband has no remaining tradeable warrants
- ➤AVERSA Fentanyl estimated at $80 million to $200 million peak annual US sales
ORLANDO, Fla., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB), announced today that it has seen 272,671 NTRBW warrants exercised at a strike price of $6.43 for proceeds to the company of $1,753,274.53. NTRBW warrants expired on September 30 with no extension. The Company has no remaining tradeable warrants.
The primary use of proceeds will be used towards the remaining clinical development of AVERSA Fentanyl and submission of its NDA with the FDA for marketing approval. AVERSA Fentanyl has the potential to become the world's first opioid patch with abuse deterrent properties and is estimated it could reach peak annual US sales of $80 million to $200 million.
Get started
Create a free account to read the full story.